Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Touguinho – page 20

697 clinical trials in Touguinho, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Touguinho at a glance
697
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

697 trials in Touguinho

Open in trial search

Study of isatuximab, belumosudil and dexamethasone combination treatment for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Belumosudil Mesilate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of isatuximab, pomalidomide and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of isatuximab, evorpacept and dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Karolinska University Hospital

Study on the Effects of Filgotinib for Children and Teenagers with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Filgotinib
  • Sponsor:Alfasigma S.p.A.

Colitis ulcerative+1

Recruiting

Study of Vedolizumab for Children with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years
  • Substances:Vedolizumab
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Hypertonic bladder

Not yet recruiting

Safety and Efficacy of Intravesical Clostridium botulinum Neurotoxin Type A (150 kD) for Idiopathic Overactive Bladder in Women

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:IncobotulinumtoxinA
  • Sponsor:Vensica Medical Ltd.

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:REGN9933
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Touguinho

What the registry says about research in the country

01 Mental Health Research

Clinical investigations focusing on Major Depressive Disorder (MDD) with concurrent insomnia symptoms, exploring innovative therapeutic approaches through combination treatments.

  • Depression Management
  • Sleep Disorders
  • Combination Therapy

The research evaluates the effectiveness of seltorexant as an adjunctive therapy alongside traditional antidepressants, specifically targeting patients who haven't responded adequately to standard SSRI/SNRI treatments.

02 Treatment Resistance Studies

Innovative research examining new therapeutic options for patients with treatment-resistant depression, focusing on dual-action approaches that address both mood and sleep disturbances.

  • Medication Augmentation
  • Symptom Management
  • Long-term Outcomes

The studies aim to evaluate both immediate therapeutic benefits and long-term effectiveness in preventing symptom relapse.

03 Sleep-Depression Interface

Groundbreaking research exploring the connection between sleep disorders and major depression, investigating integrated treatment approaches for better patient outcomes.

  • Sleep Quality
  • Mood Regulation
  • Combined Symptoms

These trials specifically target the dual presentation of depression and insomnia, addressing multiple symptoms through innovative pharmacological interventions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.